Assay development

Our biologists adapt and develop industry standard assays needed for screening, hit confirmation and functional characterisation of new molecules.

Screening

We carry out high-throughput screening using proprietary in-house compound libraries. For antibody projects we screen antibodies for binding to the target antigen.

Hit to lead optimisation

Our medicinal chemists develop structure-activity relationships (SAR) to improve potency, solubility and physico-chemical properties of hit series to turn them into drug-like molecules. For antibody projects we generate humanised or fully human antibodies and engineer them to obtain optimal binding affinity, functional efficacy and robust biophysical properties to generate a lead candidate.

Proof of concept

We evaluate our candidate compounds and antibodies in a range of relevant models, including human tissue, to demonstrate disease relevance and target engagement.

Partnering

We develop novel IP and a robust supporting data package suitable for partnering to pharmaceutical or biotechnology companies.

Accessing our expertise

Teams of nearly 80 scientists in our new Centre for Therapeutics.

Discovery offering:

  • ADME/DMPK
  • Assay development
  • Antibody biophysical characterisation
  • Antibody engineering
  • Antibody humanisation
  • High-throughput screening
  • Medicinal chemistry
  • Pharmacology
  • Small molecule libraries
  • Structural biology in silicoscreening

Screening against our compound library

120,000+ compounds, including:

  • Annotated sets of pharmacologically active compounds
  • Approved drugs
  • Fragments
  • Ion channel focused compounds
  • Kinase targeting compounds
  • Natural products
  • Protein-protein interaction targeting compounds